TIM-3

[Cell Death & Disease] Investigators characterized the role of T cell immunoglobulin and mucin domain containing 3 (TIM-3) in restimulation-induced cell death regulation.

[Oncogenesis] Researchers investigated the effects of Bruton’s tyrosine kinase (BTK) on oncurrent chemoradiotherapy-resistant oral squamous cell carcinoma tissues (OSCC). The effect of ibrutinib, a first-in-class BTK inhibitor, was tested on stem cell-like OSCC tumorspheres.

[Immunity] The role of SARS-CoV-2-specific T cell immunity, its relationship to antibodies, and pre-existing immunity against endemic coronaviruses (huCoV), which has been hypothesized to be protective, were investigated in healthy donors, recovered, and active COVID-19 patients.

[Nature Communications] Scientist showed that PD-1 contributed to the persistence of PD-1+TIM-3+ T cells by binding to the TIM-3 ligand galectin-9 and attenuated Gal-9/TIM-3-induced cell death.

[Cell Reports Medicine] Scientists investigated the impact of chemotherapy on the tumor immune microenvironment. They treated human liver metastases slices with 5-fluorouracil plus either irinotecan or oxaliplatin, then performed single-cell transcriptome analyses.

[Bioscience Reports] Tim-3 was overexpressed in vascular endothelial HMVECs and HUVECs and in vitro assays were used to determine that Tim-3 promoted cell proliferation, migration, invasion and tube formation through activating cyclin D1, Ras homolog gene family member A and vascular endothelial growth factor receptor 2.